Denali Therapeutics (DNLI) FY2022 results: revenue $108 million, up 122.9% on the year
Denali Therapeutics Inc. (DNLI) reported revenue of $108 million for fiscal 2022, the year ended 31 December 2022, up 122.9% on the year before. Net income was -$326 million, and diluted earnings per share $-2.60. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2023.
Revenue
$108 million
+122.9% on the year
FY2016FY2022
Operating margin
-314.2%
-607.8% a year earlier
FY2016FY2022
Net income
-$326 million
FY2016FY2022
Diluted EPS
-$2.60
FY2016FY2022
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Operating cash flow
-245
-211
416
Capital expenditure
17.8
8.5
3.1
+109.8%
Free cash flow
-263
-220
413
Free cash flow margin
-242.1%
-451.9%
123.1%
Cash from investing
-141
-21.6
-623
Cash from financing
311
19.3
635
+1,505.7%
Depreciation and amortisation
10.4
8.6
8.5
+20.8%
Share-based compensation
99.8
85.2
50.4
+17.1%
Diluted shares, weighted
126m
122m
113m
+3.3%
Shares outstanding at period end
136m
122m
121m
+11.2%
Balance sheet
$ million
FY2022
FY2021
FY2020
On the year
Last 8 years
Shareholders' equity
1,042
962
1,151
+8.3%
Debt
0.0
0.0
0.0
Operating lease liabilities
53.0
58.6
64.2
-9.4%
Other liabilities
365
383
390
-4.8%
Total liabilities and equity
1,460
1,404
1,604
+4.0%
Fixed assets
44.1
38.9
40.8
+13.4%
Investments
1,118
997
995
+12.1%
Cash and equivalents
218
293
507
-25.7%
Receivables
n/a
n/a
8.6
Other assets
79.9
74.4
52.4
+7.4%
Total assets
1,460
1,404
1,604
+4.0%
10-K for the year ended 31 December 2022, filed 27 February 2023: the filing.